ArticleOncology reviews2019

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.

Gilbert Lazarus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.